ReviewEndocrine reviews2017
Dihydrotestosterone: Biochemistry, Physiology, and Clinical Implications of Elevated Blood Levels.
Review in Endocrine reviews, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 118 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
118 citing papers in PubMed, 227 citations in OpenAlex.
- Non-Genomic Actions of Testosterone Metabolites on Uterine Contractility in Rats.Pharmaceutics · 2026Article
- Androgen-Modulating Drugs and Severe Complications After ST-Elevation Myocardial Infarction.JAMA network open · 2026Article
- A non-canonical androgen signaling pathway drives microglial activation and tau pathology in females.Research square · 2026Article
- The non-monotonic dose-effect of resveratrol on testicular steroidogenesis in male arctic foxes (Vulpes lagopus): Mechanisms revealed by integrated transcriptomic and metabolomic analyses.Veterinary and animal science · 2026Article
- The role of the cGAS-STING pathway in male reproductive disorders.Molecular biology reports · 2026Review
- Testosterone and cancers: biological functions, molecular mechanisms and therapy.Molecular cancer · 2026Review
- Single-cell and spatial transcriptome analysis reveals the potential therapeutic targets for testicular sex cord-stromal cell tumor.Biomarker research · 2026Article
- 5α-Reductase underscores the development of pectoral fin breeding tubercles in zebrafish.Communications biology · 2026Article
- Binding of Steroid Hormones to the FA1 and FA6 Sites of Human Serum Albumin through Computational Biology and Quantum Biochemistry.ACS omega · 2026Article
- Article
- Interactions between extracellular vesicles and hormones: review.Animal bioscience · 2026Article
- Sex Hormones Attenuate Pro-Inflammatory Gene Expression in Nucleus Pulposus and Annulus Fibrosus Cells in a Cell-Type Specific Manner.JOR spine · 2026Article
- Advances in Research on Models of Oligoasthenozoospermia.Reproductive sciences (Thousand Oaks, Calif.) · 2026Review
- The testobolome in microbial testosterone metabolism and human health.NPJ biofilms and microbiomes · 2026Review
- Pathophysiology of androgen-associated endothelial cell dysfunction in phenotype A polycystic ovarian syndrome revealed by iPSCs modeling.Frontiers in endocrinology · 2026Article
- Review
- Androgen Effects on Amyloid Precursor Protein Processing Pathways in Cancer: A Systematic Review.Current issues in molecular biology · 2025Review
- Simultaneous Target-Mediated Drug Disposition-Pharmacodynamic (TMDD-PD) Modeling of Finasteride and Dutasteride: Impact of Target Binding and Turnover on Non-linear Pharmacokinetics.The AAPS journal · 2025Article
- Discovery and development of steroidal enzyme inhibitors as anti-cancer drugs: state-of-the-art and future perspectives.Journal of enzyme inhibition and medicinal chemistry · 2025Review
- The intricate interplay between circadian rhythm, androgen signaling, hormone therapy, and cellular senescence in prostate cancer.Cancer metastasis reviews · 2025Review
58 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
Benefits associated with lowered serum DHT levels after 5α-reductase inhibitor (5AR-I) therapy in men have contributed to a misconception that circulating DHT levels are an important stimulus for androgenic action in target tissues (e.g., prostate). Yet evidence from clinical studies indicates that intracellular concentrations of androgens (particularly in androgen-sensitive tissues) are essentially independent of circulating levels. To assess the clinical significance of modest elevations in serum DHT and the DHT/testosterone (T) ratio observed in response to common T replacement therapy, a comprehensive review of the published literature was performed to identify relevant data. Although the primary focus of this review is about DHT in men, we also provide a brief overview of DHT in women. The available published data are limited by the lack of large, well-controlled studies of long duration that are sufficiently powered to expose subtle safety signals. Nonetheless, the preponderance of available clinical data indicates that modest elevations in circulating levels of DHT in response to androgen therapy should not be of concern in clinical practice. Elevated DHT has not been associated with increased risk of prostate disease (e.g., cancer or benign hyperplasia) nor does it appear to have any systemic effects on cardiovascular disease safety parameters (including increased risk of polycythemia) beyond those commonly observed with available T preparations. Well-controlled, long-term studies of transdermal DHT preparations have failed to identify safety signals unique to markedly elevated circulating DHT concentrations or signals materially different from T.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.